A week ago, Oppenheimer downgraded Endo Pharmaceuticals from Outperform to Perform. The stock closed at $30.66, which is 8.6% higher than the price one week ago ($28.23).
In the past 52 weeks, shares of Endo Pharmaceuticals have traded between a low of $25.00 and a high of $44.53 and are now at $30.40, which is 22% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.2% while the 50-day MA has advanced 0.7%.
There is potential upside of 9.6% for shares of Endo Pharmaceuticals based on a current price of $30.40 and an average consensus analyst price target of $33.31. The stock should find initial support at its 200-day moving average (MA) of $30.27 and further support at its 50-day MA of $27.56.
Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo's products include Percocet, Percodan, and Lidoderm.